TW202239403A

TW202239403A - 吡咯并吡啶衍生物用於預防或治療發炎疾病之新穎用途

吡咯并吡啶衍生物用於預防或治療發炎疾病之新穎用途 Download PDF

Info

Publication number: TW202239403A
Authority: TW; Taiwan
Prior art keywords: disease; inflammatory; chemical formula; compound; patient
Prior art date: 2020-12-09

Application number

TW110146107A

Other languages

English (en)

Chinese (zh)

Inventor

金秀燦

金大權

徐東赫

金炫炅

金聖桓

黃惠敏

崔智恩

Original Assignee

韓商沃若諾伊公司

Priority date

2020-12-09

Filing date

2021-12-09

Publication date

2022-10-16

2021-12-09 Application filed by 韓商沃若諾伊公司 filed Critical 韓商沃若諾伊公司

2022-10-16 Publication of TW202239403A publication Critical patent/TW202239403A/zh

Links

208000027866 inflammatory disease Diseases 0.000 title claims abstract description 55
150000001875 compounds Chemical class 0.000 claims abstract description 138
239000000126 substance Substances 0.000 claims abstract description 63
150000003839 salts Chemical class 0.000 claims abstract description 60
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 51
238000011282 treatment Methods 0.000 claims abstract description 35
102000004127 Cytokines Human genes 0.000 claims abstract description 25
108090000695 Cytokines Proteins 0.000 claims abstract description 25
208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 25
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 14
239000004480 active ingredient Substances 0.000 claims abstract description 13
230000002265 prevention Effects 0.000 claims abstract description 12
102000001253 Protein Kinase Human genes 0.000 claims abstract description 11
108060006633 protein kinase Proteins 0.000 claims abstract description 11
206010025135 lupus erythematosus Diseases 0.000 claims abstract description 8
238000000034 method Methods 0.000 claims description 78
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
-1 3-methoxy-4-((4-(methylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino ) phenyl Chemical group 0.000 claims description 38
206010061218 Inflammation Diseases 0.000 claims description 36
230000004054 inflammatory process Effects 0.000 claims description 36
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 35
201000010099 disease Diseases 0.000 claims description 29
230000000770 proinflammatory effect Effects 0.000 claims description 28
208000006673 asthma Diseases 0.000 claims description 27
239000003814 drug Substances 0.000 claims description 27
206010020751 Hypersensitivity Diseases 0.000 claims description 24
125000000217 alkyl group Chemical group 0.000 claims description 24
210000001519 tissue Anatomy 0.000 claims description 24
206010012438 Dermatitis atopic Diseases 0.000 claims description 23
201000008937 atopic dermatitis Diseases 0.000 claims description 23
208000009329 Graft vs Host Disease Diseases 0.000 claims description 21
201000004681 Psoriasis Diseases 0.000 claims description 21
208000024908 graft versus host disease Diseases 0.000 claims description 21
230000007815 allergy Effects 0.000 claims description 19
239000003795 chemical substances by application Substances 0.000 claims description 19
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 18
229910052739 hydrogen Inorganic materials 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 18
230000001684 chronic effect Effects 0.000 claims description 17
206010012601 diabetes mellitus Diseases 0.000 claims description 17
108090001005 Interleukin-6 Proteins 0.000 claims description 16
102000004889 Interleukin-6 Human genes 0.000 claims description 16
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 16
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 15
108010036949 Cyclosporine Proteins 0.000 claims description 15
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 15
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 15
125000001188 haloalkyl group Chemical group 0.000 claims description 15
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 14
201000004624 Dermatitis Diseases 0.000 claims description 14
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 14
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 14
CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 14
108050003558 Interleukin-17 Proteins 0.000 claims description 13
102000013691 Interleukin-17 Human genes 0.000 claims description 13
210000004027 cell Anatomy 0.000 claims description 13
NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 claims description 13
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims description 12
108010008165 Etanercept Proteins 0.000 claims description 12
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
208000026935 allergic disease Diseases 0.000 claims description 12
239000000812 cholinergic antagonist Substances 0.000 claims description 12
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 12
150000002431 hydrogen Chemical class 0.000 claims description 12
201000008482 osteoarthritis Diseases 0.000 claims description 12
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 11
230000004069 differentiation Effects 0.000 claims description 11
208000035475 disorder Diseases 0.000 claims description 11
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 11
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 10
206010009900 Colitis ulcerative Diseases 0.000 claims description 10
208000011231 Crohn disease Diseases 0.000 claims description 10
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 10
QSXMZJGGEWYVCN-UHFFFAOYSA-N Pirbuterol acetate Chemical compound CC(O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 QSXMZJGGEWYVCN-UHFFFAOYSA-N 0.000 claims description 10
210000001744 T-lymphocyte Anatomy 0.000 claims description 10
201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
208000004631 alopecia areata Diseases 0.000 claims description 10
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 10
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 10
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 10
239000003112 inhibitor Substances 0.000 claims description 10
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 10
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 10
210000003289 regulatory T cell Anatomy 0.000 claims description 10
229960004641 rituximab Drugs 0.000 claims description 10
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 10
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 9
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 9
201000007100 Pharyngitis Diseases 0.000 claims description 9
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 9
239000004012 Tofacitinib Substances 0.000 claims description 9
206010046851 Uveitis Diseases 0.000 claims description 9
206010069351 acute lung injury Diseases 0.000 claims description 9
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 9
206010009887 colitis Diseases 0.000 claims description 9
229960003957 dexamethasone Drugs 0.000 claims description 9
229920002674 hyaluronan Polymers 0.000 claims description 9
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 9
229960000485 methotrexate Drugs 0.000 claims description 9
230000000414 obstructive effect Effects 0.000 claims description 9
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 9
208000023504 respiratory system disease Diseases 0.000 claims description 9
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 9
208000011580 syndromic disease Diseases 0.000 claims description 9
229960001350 tofacitinib Drugs 0.000 claims description 9
UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 9
206010044008 tonsillitis Diseases 0.000 claims description 9
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 9
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 9
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 claims description 8
206010014950 Eosinophilia Diseases 0.000 claims description 8
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
206010039710 Scleroderma Diseases 0.000 claims description 8
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 8
229960001265 ciclosporin Drugs 0.000 claims description 8
229960000265 cromoglicic acid Drugs 0.000 claims description 8
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 8
BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims description 8
229920000669 heparin Polymers 0.000 claims description 8
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims description 8
WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 claims description 8
201000008383 nephritis Diseases 0.000 claims description 8
229920001223 polyethylene glycol Polymers 0.000 claims description 8
201000007094 prostatitis Diseases 0.000 claims description 8
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 7
206010010741 Conjunctivitis Diseases 0.000 claims description 7
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 7
102000004388 Interleukin-4 Human genes 0.000 claims description 7
108090000978 Interleukin-4 Proteins 0.000 claims description 7
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 7
229960001138 acetylsalicylic acid Drugs 0.000 claims description 7
230000000172 allergic effect Effects 0.000 claims description 7
JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 claims description 7
208000010668 atopic eczema Diseases 0.000 claims description 7
230000001363 autoimmune Effects 0.000 claims description 7
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 7
229960000590 celecoxib Drugs 0.000 claims description 7
239000003246 corticosteroid Substances 0.000 claims description 7
229960001334 corticosteroids Drugs 0.000 claims description 7
229960005293 etodolac Drugs 0.000 claims description 7
229960000890 hydrocortisone Drugs 0.000 claims description 7
229960001680 ibuprofen Drugs 0.000 claims description 7
201000006417 multiple sclerosis Diseases 0.000 claims description 7
229960002009 naproxen Drugs 0.000 claims description 7
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 7
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 7
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 7
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
108010019625 Atazanavir Sulfate Proteins 0.000 claims description 6
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 6
XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 6
201000009273 Endometriosis Diseases 0.000 claims description 6
108010032976 Enfuvirtide Proteins 0.000 claims description 6
102000017761 Interleukin-33 Human genes 0.000 claims description 6
108010067003 Interleukin-33 Proteins 0.000 claims description 6
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 6
201000002481 Myositis Diseases 0.000 claims description 6
206010068319 Oropharyngeal pain Diseases 0.000 claims description 6
208000001132 Osteoporosis Diseases 0.000 claims description 6
206010033078 Otitis media Diseases 0.000 claims description 6
201000007737 Retinal degeneration Diseases 0.000 claims description 6
206010038910 Retinitis Diseases 0.000 claims description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 6
206010047115 Vasculitis Diseases 0.000 claims description 6
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 6
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 6
206010006451 bronchitis Diseases 0.000 claims description 6
208000013507 chronic prostatitis Diseases 0.000 claims description 6
229960004397 cyclophosphamide Drugs 0.000 claims description 6
201000003146 cystitis Diseases 0.000 claims description 6
CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 6
201000001981 dermatomyositis Diseases 0.000 claims description 6
208000033679 diabetic kidney disease Diseases 0.000 claims description 6
229960001259 diclofenac Drugs 0.000 claims description 6
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 6
229960002656 didanosine Drugs 0.000 claims description 6
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 claims description 6
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 6
229940073621 enbrel Drugs 0.000 claims description 6
PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims description 6
229960000403 etanercept Drugs 0.000 claims description 6
PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 claims description 6
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 6
208000017169 kidney disease Diseases 0.000 claims description 6
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 6
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 6
229940063718 lodine Drugs 0.000 claims description 6
208000002780 macular degeneration Diseases 0.000 claims description 6
GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 6
206010028417 myasthenia gravis Diseases 0.000 claims description 6
229960005489 paracetamol Drugs 0.000 claims description 6
CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 claims description 6
230000009467 reduction Effects 0.000 claims description 6
230000004258 retinal degeneration Effects 0.000 claims description 6
206010039083 rhinitis Diseases 0.000 claims description 6
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 6
229960001852 saquinavir Drugs 0.000 claims description 6
201000009890 sinusitis Diseases 0.000 claims description 6
229960001940 sulfasalazine Drugs 0.000 claims description 6
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 6
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 6
SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 claims description 6
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
229960004528 vincristine Drugs 0.000 claims description 6
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
229960000523 zalcitabine Drugs 0.000 claims description 6
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 5
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 5
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 5
NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 5
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 5
VNVNZKCCDVFGAP-NMFAMCKASA-N 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol 2,3-dihydroxybutanedioic acid Chemical compound OC(C(O)C(O)=O)C(O)=O.CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1 VNVNZKCCDVFGAP-NMFAMCKASA-N 0.000 claims description 5
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 5
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 5
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 5
PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 claims description 5
208000015943 Coeliac disease Diseases 0.000 claims description 5
206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
208000004232 Enteritis Diseases 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 5
206010035664 Pneumonia Diseases 0.000 claims description 5
206010039085 Rhinitis allergic Diseases 0.000 claims description 5
DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 claims description 5
229960002964 adalimumab Drugs 0.000 claims description 5
208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
201000010105 allergic rhinitis Diseases 0.000 claims description 5
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 5
229960003556 aminophylline Drugs 0.000 claims description 5
229960001830 amprenavir Drugs 0.000 claims description 5
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 5
229960004238 anakinra Drugs 0.000 claims description 5
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 5
239000003430 antimalarial agent Substances 0.000 claims description 5
229940033495 antimalarials Drugs 0.000 claims description 5
AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 5
229940098165 atrovent Drugs 0.000 claims description 5
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims description 5
229960005207 auranofin Drugs 0.000 claims description 5
229960002170 azathioprine Drugs 0.000 claims description 5
229940064856 azulfidine Drugs 0.000 claims description 5
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 5
229960004436 budesonide Drugs 0.000 claims description 5
229960003115 certolizumab pegol Drugs 0.000 claims description 5
KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 claims description 5
229960003677 chloroquine Drugs 0.000 claims description 5
229960001338 colchicine Drugs 0.000 claims description 5
229930182912 cyclosporin Natural products 0.000 claims description 5
230000006378 damage Effects 0.000 claims description 5
CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 claims description 5
229940103439 dulera Drugs 0.000 claims description 5
201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 5
208000030533 eye disease Diseases 0.000 claims description 5
229960000676 flunisolide Drugs 0.000 claims description 5
229940107791 foradil Drugs 0.000 claims description 5
229960002848 formoterol Drugs 0.000 claims description 5
229960001743 golimumab Drugs 0.000 claims description 5
229940048921 humira Drugs 0.000 claims description 5
229960004171 hydroxychloroquine Drugs 0.000 claims description 5
208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 5
229960000598 infliximab Drugs 0.000 claims description 5
229940125369 inhaled corticosteroids Drugs 0.000 claims description 5
229960001361 ipratropium bromide Drugs 0.000 claims description 5
229960000681 leflunomide Drugs 0.000 claims description 5
229950008204 levosalbutamol Drugs 0.000 claims description 5
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 5
239000000347 magnesium hydroxide Substances 0.000 claims description 5
235000012254 magnesium hydroxide Nutrition 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
229960001664 mometasone Drugs 0.000 claims description 5
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 5
RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 claims description 5
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 5
229960002657 orciprenaline Drugs 0.000 claims description 5
230000000737 periodic effect Effects 0.000 claims description 5
229960004994 pirbuterol acetate Drugs 0.000 claims description 5
229940072689 plaquenil Drugs 0.000 claims description 5
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 5
229960003081 probenecid Drugs 0.000 claims description 5
229940063566 proventil Drugs 0.000 claims description 5
229940014063 qvar Drugs 0.000 claims description 5
229940061969 rheumatrex Drugs 0.000 claims description 5
229960002052 salbutamol Drugs 0.000 claims description 5
229940090585 serevent Drugs 0.000 claims description 5
229940046810 spiriva Drugs 0.000 claims description 5
229940035073 symbicort Drugs 0.000 claims description 5
KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims description 5
229960005105 terbutaline sulfate Drugs 0.000 claims description 5
229940089554 theo-24 Drugs 0.000 claims description 5
229960000278 theophylline Drugs 0.000 claims description 5
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 5
229940110309 tiotropium Drugs 0.000 claims description 5
229960003989 tocilizumab Drugs 0.000 claims description 5
229960002117 triamcinolone acetonide Drugs 0.000 claims description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
229940089541 uniphyl Drugs 0.000 claims description 5
229940070384 ventolin Drugs 0.000 claims description 5
229960005080 warfarin Drugs 0.000 claims description 5
229940061637 xopenex Drugs 0.000 claims description 5
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 4
LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 claims description 4
208000026872 Addison Disease Diseases 0.000 claims description 4
XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims description 4
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 4
229920001268 Cholestyramine Polymers 0.000 claims description 4
206010061818 Disease progression Diseases 0.000 claims description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
102100037850 Interferon gamma Human genes 0.000 claims description 4
108010074328 Interferon-gamma Proteins 0.000 claims description 4
102000003814 Interleukin-10 Human genes 0.000 claims description 4
108090000174 Interleukin-10 Proteins 0.000 claims description 4
102000013462 Interleukin-12 Human genes 0.000 claims description 4
108010065805 Interleukin-12 Proteins 0.000 claims description 4
102000003816 Interleukin-13 Human genes 0.000 claims description 4
108090000176 Interleukin-13 Proteins 0.000 claims description 4
102000013264 Interleukin-23 Human genes 0.000 claims description 4
108010065637 Interleukin-23 Proteins 0.000 claims description 4
208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 4
229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 4
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 4
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 4
JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 claims description 4
229960003697 abatacept Drugs 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
229940119059 actemra Drugs 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
208000037883 airway inflammation Diseases 0.000 claims description 4
229940040386 amitiza Drugs 0.000 claims description 4
208000007502 anemia Diseases 0.000 claims description 4
230000001142 anti-diarrhea Effects 0.000 claims description 4
239000003146 anticoagulant agent Substances 0.000 claims description 4
229940127219 anticoagulant drug Drugs 0.000 claims description 4
229940125714 antidiarrheal agent Drugs 0.000 claims description 4
239000003793 antidiarrheal agent Substances 0.000 claims description 4
229940124575 antispasmodic agent Drugs 0.000 claims description 4
229940059756 arava Drugs 0.000 claims description 4
229940094361 arcalyst Drugs 0.000 claims description 4
229940124748 beta 2 agonist Drugs 0.000 claims description 4
239000003613 bile acid Substances 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 4
229960001838 canakinumab Drugs 0.000 claims description 4
229960004630 chlorambucil Drugs 0.000 claims description 4
208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 4
229940090100 cimzia Drugs 0.000 claims description 4
229940002157 colcrys Drugs 0.000 claims description 4
229940072645 coumadin Drugs 0.000 claims description 4
229940064774 cuprimine Drugs 0.000 claims description 4
229940075911 depen Drugs 0.000 claims description 4
230000005750 disease progression Effects 0.000 claims description 4
229940099198 dulcolax Drugs 0.000 claims description 4
229960005101 febuxostat Drugs 0.000 claims description 4
150000002343 gold Chemical class 0.000 claims description 4
239000010931 gold Substances 0.000 claims description 4
229910052737 gold Inorganic materials 0.000 claims description 4
ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 claims description 4
IRPYFWIZKIOHQN-XTZHGVARSA-N gold;[(2r,3r,4s,5r,6s)-3,4,5-triacetyloxy-6-sulfanyloxan-2-yl]methyl acetate;triethylphosphane Chemical compound [Au].CC[PH+](CC)CC.CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O IRPYFWIZKIOHQN-XTZHGVARSA-N 0.000 claims description 4
229960002897 heparin Drugs 0.000 claims description 4
208000002557 hidradenitis Diseases 0.000 claims description 4
201000007162 hidradenitis suppurativa Diseases 0.000 claims description 4
229940095970 imodium Drugs 0.000 claims description 4
229940073062 imuran Drugs 0.000 claims description 4
201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
229940054136 kineret Drugs 0.000 claims description 4
229940033984 lamivudine / zidovudine Drugs 0.000 claims description 4
239000008141 laxative Substances 0.000 claims description 4
229940125722 laxative agent Drugs 0.000 claims description 4
229940063725 leukeran Drugs 0.000 claims description 4
229940087973 lomotil Drugs 0.000 claims description 4
229960001571 loperamide Drugs 0.000 claims description 4
229940060963 lotronex Drugs 0.000 claims description 4
229960000345 lubiprostone Drugs 0.000 claims description 4
229940060946 miralax Drugs 0.000 claims description 4
229960005127 montelukast Drugs 0.000 claims description 4
229940090001 myochrysine Drugs 0.000 claims description 4
229960000884 nelfinavir Drugs 0.000 claims description 4
229960000470 omalizumab Drugs 0.000 claims description 4
229940035567 orencia Drugs 0.000 claims description 4
229960001639 penicillamine Drugs 0.000 claims description 4
229940116176 remicade Drugs 0.000 claims description 4
238000007634 remodeling Methods 0.000 claims description 4
229940063638 ridaura Drugs 0.000 claims description 4
229960000311 ritonavir Drugs 0.000 claims description 4
229960005018 salmeterol xinafoate Drugs 0.000 claims description 4
229940063122 sandimmune Drugs 0.000 claims description 4
IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 claims description 4
229940063651 senokot Drugs 0.000 claims description 4
229940068638 simponi Drugs 0.000 claims description 4
208000003265 stomatitis Diseases 0.000 claims description 4
230000009885 systemic effect Effects 0.000 claims description 4
229940063477 uloric Drugs 0.000 claims description 4
201000005539 vernal conjunctivitis Diseases 0.000 claims description 4
229940099073 xolair Drugs 0.000 claims description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
208000022309 Alcoholic Liver disease Diseases 0.000 claims description 3
208000032467 Aplastic anaemia Diseases 0.000 claims description 3
206010003011 Appendicitis Diseases 0.000 claims description 3
AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 3
208000009137 Behcet syndrome Diseases 0.000 claims description 3
208000019838 Blood disease Diseases 0.000 claims description 3
206010006448 Bronchiolitis Diseases 0.000 claims description 3
206010006811 Bursitis Diseases 0.000 claims description 3
206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
208000006029 Cardiomegaly Diseases 0.000 claims description 3
208000002177 Cataract Diseases 0.000 claims description 3
206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 3
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
201000003883 Cystic fibrosis Diseases 0.000 claims description 3
208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
206010013774 Dry eye Diseases 0.000 claims description 3
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 3
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 3
208000004145 Endometritis Diseases 0.000 claims description 3
206010016228 Fasciitis Diseases 0.000 claims description 3
208000007882 Gastritis Diseases 0.000 claims description 3
208000005577 Gastroenteritis Diseases 0.000 claims description 3
208000010412 Glaucoma Diseases 0.000 claims description 3
208000022461 Glomerular disease Diseases 0.000 claims description 3
206010053759 Growth retardation Diseases 0.000 claims description 3
206010019233 Headaches Diseases 0.000 claims description 3
206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
229940127590 IRAK4 inhibitor Drugs 0.000 claims description 3
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
108010050904 Interferons Proteins 0.000 claims description 3
102000014150 Interferons Human genes 0.000 claims description 3
102100030703 Interleukin-22 Human genes 0.000 claims description 3
208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
208000029523 Interstitial Lung disease Diseases 0.000 claims description 3
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 3
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 3
201000008197 Laryngitis Diseases 0.000 claims description 3
206010024238 Leptospirosis Diseases 0.000 claims description 3
208000004852 Lung Injury Diseases 0.000 claims description 3
208000019693 Lung disease Diseases 0.000 claims description 3
201000009906 Meningitis Diseases 0.000 claims description 3
206010027406 Mesothelioma Diseases 0.000 claims description 3
206010028289 Muscle atrophy Diseases 0.000 claims description 3
208000003926 Myelitis Diseases 0.000 claims description 3
208000009525 Myocarditis Diseases 0.000 claims description 3
206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
208000008589 Obesity Diseases 0.000 claims description 3
206010031149 Osteitis Diseases 0.000 claims description 3
208000010191 Osteitis Deformans Diseases 0.000 claims description 3
208000005141 Otitis Diseases 0.000 claims description 3
208000027868 Paget disease Diseases 0.000 claims description 3
208000002193 Pain Diseases 0.000 claims description 3
206010033645 Pancreatitis Diseases 0.000 claims description 3
208000006735 Periostitis Diseases 0.000 claims description 3
206010065159 Polychondritis Diseases 0.000 claims description 3
206010036105 Polyneuropathy Diseases 0.000 claims description 3
206010036774 Proctitis Diseases 0.000 claims description 3
206010037596 Pyelonephritis Diseases 0.000 claims description 3
208000017442 Retinal disease Diseases 0.000 claims description 3
208000007893 Salpingitis Diseases 0.000 claims description 3
201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
206010042953 Systemic sclerosis Diseases 0.000 claims description 3
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
208000000491 Tendinopathy Diseases 0.000 claims description 3
206010043255 Tendonitis Diseases 0.000 claims description 3
SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 3
206010069363 Traumatic lung injury Diseases 0.000 claims description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
208000006374 Uterine Cervicitis Diseases 0.000 claims description 3
206010046914 Vaginal infection Diseases 0.000 claims description 3
201000008100 Vaginitis Diseases 0.000 claims description 3
UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 claims description 3
GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 claims description 3
229960004748 abacavir Drugs 0.000 claims description 3
229940030360 abacavir / lamivudine Drugs 0.000 claims description 3
WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 claims description 3
230000032683 aging Effects 0.000 claims description 3
229960003550 alosetron Drugs 0.000 claims description 3
230000001078 anti-cholinergic effect Effects 0.000 claims description 3
229960001164 apremilast Drugs 0.000 claims description 3
IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 claims description 3
229940030139 aptivus Drugs 0.000 claims description 3
229960003277 atazanavir Drugs 0.000 claims description 3
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
229950000971 baricitinib Drugs 0.000 claims description 3
XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims description 3
229950000210 beclometasone dipropionate Drugs 0.000 claims description 3
229960003270 belimumab Drugs 0.000 claims description 3
229940090012 bentyl Drugs 0.000 claims description 3
229960002537 betamethasone Drugs 0.000 claims description 3
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
208000010217 blepharitis Diseases 0.000 claims description 3
208000018339 bone inflammation disease Diseases 0.000 claims description 3
230000010083 bronchial hyperresponsiveness Effects 0.000 claims description 3
PMDQGYMGQKTCSX-HQROKSDRSA-L calcium;[(2r,3s)-1-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-[[(3s)-oxolan-3-yl]oxycarbonylamino]-4-phenylbutan-2-yl] phosphate Chemical compound [Ca+2].C([C@@H]([C@H](OP([O-])([O-])=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 PMDQGYMGQKTCSX-HQROKSDRSA-L 0.000 claims description 3
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 3
230000001925 catabolic effect Effects 0.000 claims description 3
206010008323 cervicitis Diseases 0.000 claims description 3
238000006243 chemical reaction Methods 0.000 claims description 3
208000003167 cholangitis Diseases 0.000 claims description 3
201000001352 cholecystitis Diseases 0.000 claims description 3
229940014461 combivir Drugs 0.000 claims description 3
229960004544 cortisone Drugs 0.000 claims description 3
229940088900 crixivan Drugs 0.000 claims description 3
229960005107 darunavir Drugs 0.000 claims description 3
229940026692 decadron Drugs 0.000 claims description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 3
239000007884 disintegrant Substances 0.000 claims description 3
208000007784 diverticulitis Diseases 0.000 claims description 3
208000019258 ear infection Diseases 0.000 claims description 3
229960003804 efavirenz Drugs 0.000 claims description 3
229960000366 emtricitabine Drugs 0.000 claims description 3
229940001018 emtriva Drugs 0.000 claims description 3
206010014599 encephalitis Diseases 0.000 claims description 3
206010014665 endocarditis Diseases 0.000 claims description 3
229960002062 enfuvirtide Drugs 0.000 claims description 3
208000010227 enterocolitis Diseases 0.000 claims description 3
201000010063 epididymitis Diseases 0.000 claims description 3
229940072253 epivir Drugs 0.000 claims description 3
229940019131 epzicom Drugs 0.000 claims description 3
229960002049 etravirine Drugs 0.000 claims description 3
206010015907 eye allergy Diseases 0.000 claims description 3
239000000796 flavoring agent Substances 0.000 claims description 3
235000013355 food flavoring agent Nutrition 0.000 claims description 3
235000003599 food sweetener Nutrition 0.000 claims description 3
229940099052 fuzeon Drugs 0.000 claims description 3
108010074605 gamma-Globulins Proteins 0.000 claims description 3
231100000852 glomerular disease Toxicity 0.000 claims description 3
231100000001 growth retardation Toxicity 0.000 claims description 3
231100000869 headache Toxicity 0.000 claims description 3
208000019622 heart disease Diseases 0.000 claims description 3
208000014951 hematologic disease Diseases 0.000 claims description 3
208000018706 hematopoietic system disease Diseases 0.000 claims description 3
208000007475 hemolytic anemia Diseases 0.000 claims description 3
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
208000025070 hereditary periodic fever syndrome Diseases 0.000 claims description 3
229940018991 hyalgan Drugs 0.000 claims description 3
229960003160 hyaluronic acid Drugs 0.000 claims description 3
208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 3
229940071829 ilaris Drugs 0.000 claims description 3
201000008319 inclusion body myositis Diseases 0.000 claims description 3
229960001936 indinavir Drugs 0.000 claims description 3
229940124524 integrase inhibitor Drugs 0.000 claims description 3
239000002850 integrase inhibitor Substances 0.000 claims description 3
229940115474 intelence Drugs 0.000 claims description 3
229940079322 interferon Drugs 0.000 claims description 3
108010074109 interleukin-22 Proteins 0.000 claims description 3
229940088976 invirase Drugs 0.000 claims description 3
208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
229940111682 isentress Drugs 0.000 claims description 3
229940112586 kaletra Drugs 0.000 claims description 3
229960001627 lamivudine Drugs 0.000 claims description 3
229960004942 lenalidomide Drugs 0.000 claims description 3
229940113354 lexiva Drugs 0.000 claims description 3
201000011486 lichen planus Diseases 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 3
231100000515 lung injury Toxicity 0.000 claims description 3
208000027202 mammary Paget disease Diseases 0.000 claims description 3
229960004710 maraviroc Drugs 0.000 claims description 3
208000004396 mastitis Diseases 0.000 claims description 3
239000012528 membrane Substances 0.000 claims description 3
201000000585 muscular atrophy Diseases 0.000 claims description 3
229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 3
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 3
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 3
229940072250 norvir Drugs 0.000 claims description 3
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
235000020824 obesity Nutrition 0.000 claims description 3
208000005963 oophoritis Diseases 0.000 claims description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
208000008494 pericarditis Diseases 0.000 claims description 3
206010034674 peritonitis Diseases 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 3
230000007824 polyneuropathy Effects 0.000 claims description 3
229940068586 prezista Drugs 0.000 claims description 3
208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
208000002815 pulmonary hypertension Diseases 0.000 claims description 3
229960004742 raltegravir Drugs 0.000 claims description 3
230000001105 regulatory effect Effects 0.000 claims description 3
229940063627 rescriptor Drugs 0.000 claims description 3
229940064914 retrovir Drugs 0.000 claims description 3
229940120975 revlimid Drugs 0.000 claims description 3
229940107904 reyataz Drugs 0.000 claims description 3
229940031307 selzentry Drugs 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
229960001203 stavudine Drugs 0.000 claims description 3
229940054565 sustiva Drugs 0.000 claims description 3
239000003765 sweetening agent Substances 0.000 claims description 3
201000004595 synovitis Diseases 0.000 claims description 3
229940036220 synvisc Drugs 0.000 claims description 3
229960001967 tacrolimus Drugs 0.000 claims description 3
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
229950008160 tanezumab Drugs 0.000 claims description 3
201000004415 tendinitis Diseases 0.000 claims description 3
229960004556 tenofovir Drugs 0.000 claims description 3
229960001355 tenofovir disoproxil Drugs 0.000 claims description 3
206010043778 thyroiditis Diseases 0.000 claims description 3
229960000838 tipranavir Drugs 0.000 claims description 3
229940111527 trizivir Drugs 0.000 claims description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
229940099039 velcade Drugs 0.000 claims description 3
229940023080 viracept Drugs 0.000 claims description 3
229940098802 viramune Drugs 0.000 claims description 3
208000002003 vulvitis Diseases 0.000 claims description 3
229940087450 zerit Drugs 0.000 claims description 3
229940052255 ziagen Drugs 0.000 claims description 3
229960002555 zidovudine Drugs 0.000 claims description 3
206010001889 Alveolitis Diseases 0.000 claims description 2
208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 2
201000011275 Epicondylitis Diseases 0.000 claims description 2
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
208000003807 Graves Disease Diseases 0.000 claims description 2
208000015023 Graves' disease Diseases 0.000 claims description 2
201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 2
206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 2
208000031814 IgA Vasculitis Diseases 0.000 claims description 2
OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 claims description 2
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 2
206010034038 Parotitis Diseases 0.000 claims description 2
208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
240000001717 Vaccinium macrocarpon Species 0.000 claims description 2
235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 2
235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 2
208000027418 Wounds and injury Diseases 0.000 claims description 2
229960003459 allopurinol Drugs 0.000 claims description 2
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 2
230000006472 autoimmune response Effects 0.000 claims description 2
229960001467 bortezomib Drugs 0.000 claims description 2
230000024245 cell differentiation Effects 0.000 claims description 2
208000016532 chronic granulomatous disease Diseases 0.000 claims description 2
235000004634 cranberry Nutrition 0.000 claims description 2
229960005319 delavirdine Drugs 0.000 claims description 2
229960002777 dicycloverine Drugs 0.000 claims description 2
229960004192 diphenoxylate Drugs 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
208000002169 ectodermal dysplasia Diseases 0.000 claims description 2
230000002124 endocrine Effects 0.000 claims description 2
229960003142 fosamprenavir Drugs 0.000 claims description 2
MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 claims description 2
239000011521 glass Substances 0.000 claims description 2
201000003535 hypohidrotic ectodermal dysplasia Diseases 0.000 claims description 2
208000035128 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 10B Diseases 0.000 claims description 2
208000032771 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 11B Diseases 0.000 claims description 2
208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
208000014674 injury Diseases 0.000 claims description 2
229940120922 lopinavir and ritonavir Drugs 0.000 claims description 2
229960004584 methylprednisolone Drugs 0.000 claims description 2
201000005737 orchitis Diseases 0.000 claims description 2
230000002093 peripheral effect Effects 0.000 claims description 2
208000005987 polymyositis Diseases 0.000 claims description 2
229960005205 prednisolone Drugs 0.000 claims description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
229960004618 prednisone Drugs 0.000 claims description 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
229960001886 rilonacept Drugs 0.000 claims description 2
108010046141 rilonacept Proteins 0.000 claims description 2
201000000306 sarcoidosis Diseases 0.000 claims description 2
229960002930 sirolimus Drugs 0.000 claims description 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 2
125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 2
206010018364 Glomerulonephritis Diseases 0.000 claims 2
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
229940114030 abacavir / lamivudine / zidovudine Drugs 0.000 claims 2
210000003743 erythrocyte Anatomy 0.000 claims 2
LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 claims 2
150000002576 ketones Chemical class 0.000 claims 2
231100000516 lung damage Toxicity 0.000 claims 2
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
206010066091 Bronchial Hyperreactivity Diseases 0.000 claims 1
206010018691 Granuloma Diseases 0.000 claims 1
208000005647 Mumps Diseases 0.000 claims 1
206010058461 Orchitis noninfective Diseases 0.000 claims 1
206010037549 Purpura Diseases 0.000 claims 1
241001672981 Purpura Species 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
KUVIULQEHSCUHY-UHFFFAOYSA-N [2-(9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] propanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(Cl)C1C1CC(C)C(C(=O)COC(=O)CC)(OC(=O)CC)C1(C)CC2O KUVIULQEHSCUHY-UHFFFAOYSA-N 0.000 claims 1
230000002921 anti-spasmodic effect Effects 0.000 claims 1
229940049706 benzodiazepine Drugs 0.000 claims 1
150000001557 benzodiazepines Chemical class 0.000 claims 1
229910052796 boron Inorganic materials 0.000 claims 1
230000036427 bronchial hyperreactivity Effects 0.000 claims 1
230000000366 juvenile effect Effects 0.000 claims 1
206010023332 keratitis Diseases 0.000 claims 1
201000010666 keratoconjunctivitis Diseases 0.000 claims 1
208000019423 liver disease Diseases 0.000 claims 1
208000010805 mumps infectious disease Diseases 0.000 claims 1
210000003205 muscle Anatomy 0.000 claims 1
229960000689 nevirapine Drugs 0.000 claims 1
208000001297 phlebitis Diseases 0.000 claims 1
208000008423 pleurisy Diseases 0.000 claims 1
210000002307 prostate Anatomy 0.000 claims 1
229950000339 xinafoate Drugs 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 abstract description 26
239000000203 mixture Substances 0.000 abstract description 16
230000002401 inhibitory effect Effects 0.000 abstract description 15
230000006872 improvement Effects 0.000 abstract description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
229940125904 compound 1 Drugs 0.000 description 46
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 23
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
229960002751 imiquimod Drugs 0.000 description 21
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
206010014025 Ear swelling Diseases 0.000 description 11
102100040247 Tumor necrosis factor Human genes 0.000 description 11
206010003246 arthritis Diseases 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
230000000968 intestinal effect Effects 0.000 description 11
239000002904 solvent Substances 0.000 description 11
230000002354 daily effect Effects 0.000 description 10
238000011156 evaluation Methods 0.000 description 10
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 9
239000013543 active substance Substances 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
239000000428 dust Substances 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
239000006071 cream Substances 0.000 description 8
230000006698 induction Effects 0.000 description 8
238000005259 measurement Methods 0.000 description 8
238000010172 mouse model Methods 0.000 description 8
150000005255 pyrrolopyridines Chemical class 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
230000003110 anti-inflammatory effect Effects 0.000 description 7
125000000753 cycloalkyl group Chemical group 0.000 description 7
239000002158 endotoxin Substances 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
229920006008 lipopolysaccharide Polymers 0.000 description 7
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
229940124597 therapeutic agent Drugs 0.000 description 7
229930105110 Cyclosporin A Natural products 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
206010030113 Oedema Diseases 0.000 description 6
210000001072 colon Anatomy 0.000 description 6
230000002550 fecal effect Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
102000003896 Myeloperoxidases Human genes 0.000 description 5
108090000235 Myeloperoxidases Proteins 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
229920003045 dextran sodium sulfate Polymers 0.000 description 5
210000005069 ears Anatomy 0.000 description 5
230000001747 exhibiting effect Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000035699 permeability Effects 0.000 description 5
239000013641 positive control Substances 0.000 description 5
210000002345 respiratory system Anatomy 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
230000000699 topical effect Effects 0.000 description 5
102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
206010014989 Epidermolysis bullosa Diseases 0.000 description 4
206010015150 Erythema Diseases 0.000 description 4
108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 4
102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
201000011152 Pemphigus Diseases 0.000 description 4
210000000068 Th17 cell Anatomy 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000002585 base Substances 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
230000009266 disease activity Effects 0.000 description 4
231100000321 erythema Toxicity 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 description 3
102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 3
201000005569 Gout Diseases 0.000 description 3
101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
210000003423 ankle Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000005802 health problem Effects 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
230000009610 hypersensitivity Effects 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
239000013642 negative control Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
208000028169 periodontal disease Diseases 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000003449 preventive effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
239000000725 suspension Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
210000002993 trophoblast Anatomy 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
206010027654 Allergic conditions Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
208000031648 Body Weight Changes Diseases 0.000 description 2
102100021534 Calcium/calmodulin-dependent protein kinase kinase 2 Human genes 0.000 description 2
102100025228 Calcium/calmodulin-dependent protein kinase type II subunit delta Human genes 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
206010048610 Cardiotoxicity Diseases 0.000 description 2
102100034357 Casein kinase I isoform alpha Human genes 0.000 description 2
102100037402 Casein kinase I isoform delta Human genes 0.000 description 2
102100037398 Casein kinase I isoform epsilon Human genes 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102100039683 Cyclin-G-associated kinase Human genes 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
206010012468 Dermatitis herpetiformis Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
206010013710 Drug interaction Diseases 0.000 description 2
102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 description 2
102100040856 Dual specificity protein kinase CLK3 Human genes 0.000 description 2
102100040858 Dual specificity protein kinase CLK4 Human genes 0.000 description 2
102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 description 2
102100023115 Dual specificity tyrosine-phosphorylation-regulated kinase 2 Human genes 0.000 description 2
206010015218 Erythema multiforme Diseases 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101000971617 Homo sapiens Calcium/calmodulin-dependent protein kinase kinase 2 Proteins 0.000 description 2
101001077338 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit delta Proteins 0.000 description 2
101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 description 2
101001026336 Homo sapiens Casein kinase I isoform delta Proteins 0.000 description 2
101001026376 Homo sapiens Casein kinase I isoform epsilon Proteins 0.000 description 2
101000886209 Homo sapiens Cyclin-G-associated kinase Proteins 0.000 description 2
101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 description 2
101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 description 2
101000749304 Homo sapiens Dual specificity protein kinase CLK3 Proteins 0.000 description 2
101000749298 Homo sapiens Dual specificity protein kinase CLK4 Proteins 0.000 description 2
101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 description 2
101001049990 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 2 Proteins 0.000 description 2
101000867103 Homo sapiens Hormonally up-regulated neu tumor-associated kinase Proteins 0.000 description 2
101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 2
101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 2
101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 2
101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 2
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 2
101001022780 Homo sapiens Myosin light chain kinase, smooth muscle Proteins 0.000 description 2
101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 description 2
101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 2
101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 description 2
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102100036721 Insulin receptor Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 2
108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 2
102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 2
102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 2
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 2
102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 2
102000003945 NF-kappa B Human genes 0.000 description 2
108010057466 NF-kappa B Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010034277 Pemphigoid Diseases 0.000 description 2
208000027086 Pemphigus foliaceus Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 description 2
102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102100039390 Toll-like receptor 7 Human genes 0.000 description 2
102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940060265 aldara Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000004579 body weight change Effects 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
208000000594 bullous pemphigoid Diseases 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002775 capsule Substances 0.000 description 2
231100000259 cardiotoxicity Toxicity 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000007910 chewable tablet Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
229940043264 dodecyl sulfate Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
230000002327 eosinophilic effect Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229950006663 filgotinib Drugs 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
210000000224 granular leucocyte Anatomy 0.000 description 2
239000008187 granular material Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
230000001788 irregular Effects 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
208000002741 leukoplakia Diseases 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229960004963 mesalazine Drugs 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
238000003305 oral gavage Methods 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
206010057056 paraneoplastic pemphigus Diseases 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
201000001976 pemphigus vulgaris Diseases 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
206010035653 pneumoconiosis Diseases 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000012453 solvate Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000008409 synovial inflammation Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241001164374 Calyx Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
101100061188 Drosophila melanogaster dila gene Proteins 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
206010015995 Eyelid ptosis Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010018634 Gouty Arthritis Diseases 0.000 description 1
RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
101000731078 Homo sapiens Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Proteins 0.000 description 1
101001126783 Homo sapiens Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Proteins 0.000 description 1
101000701396 Homo sapiens Serine/threonine-protein kinase 33 Proteins 0.000 description 1
101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
102100031449 Hormonally up-regulated neu tumor-associated kinase Human genes 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000042838 JAK family Human genes 0.000 description 1
108091082332 JAK family Proteins 0.000 description 1
229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
229940122245 Janus kinase inhibitor Drugs 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000009233 Morning Sickness Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
208000011623 Obstructive Lung disease Diseases 0.000 description 1
241001111421 Pannus Species 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
102100032391 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Human genes 0.000 description 1
102100030278 Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
241000238711 Pyroglyphidae Species 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
102100030515 Serine/threonine-protein kinase 33 Human genes 0.000 description 1
102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
206010053262 Skin swelling Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
206010068887 Tobacco poisoning Diseases 0.000 description 1
102000002689 Toll-like receptor Human genes 0.000 description 1
108020000411 Toll-like receptor Proteins 0.000 description 1
206010065258 Tropical eosinophilia Diseases 0.000 description 1
206010045240 Type I hypersensitivity Diseases 0.000 description 1
208000034850 Vomiting in pregnancy Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
206010000496 acne Diseases 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000010085 airway hyperresponsiveness Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
208000028462 aluminosis Diseases 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
208000010123 anthracosis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000919 anti-host Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
210000000544 articulatio talocruralis Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940072224 asacol Drugs 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
DQSGVVGOPRWTKI-QVFAWCHISA-N atazanavir sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 DQSGVVGOPRWTKI-QVFAWCHISA-N 0.000 description 1
208000010216 atopic IgE responsiveness Diseases 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
150000001602 bicycloalkyls Chemical group 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000003152 bradykinin antagonist Substances 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical class CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
230000003846 cartilage breakdown Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000004953 colonic tissue Anatomy 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical compound C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
235000020805 dietary restrictions Nutrition 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
208000003401 eosinophilic granuloma Diseases 0.000 description 1
201000009580 eosinophilic pneumonia Diseases 0.000 description 1
230000036566 epidermal hyperplasia Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000007421 fluorometric assay Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
210000002175 goblet cell Anatomy 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 description 1
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
229940046533 house dust mites Drugs 0.000 description 1
102000054350 human CHI3L1 Human genes 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
230000001329 hyperkeratotic effect Effects 0.000 description 1
230000004047 hyperresponsiveness Effects 0.000 description 1
201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000004199 lung function Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229940049920 malate Drugs 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
238000006241 metabolic reaction Methods 0.000 description 1
210000001872 metatarsal bone Anatomy 0.000 description 1
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000020763 muscle atrophy Effects 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
208000007892 occupational asthma Diseases 0.000 description 1
208000014055 occupational lung disease Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
150000002942 palmitic acid derivatives Chemical class 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
201000003004 ptosis Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
201000009732 pulmonary eosinophilia Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
231100000272 reduced body weight Toxicity 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
230000007017 scission Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000013097 stability assessment Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
210000000457 tarsus Anatomy 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
230000009959 type I hypersensitivity Effects 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
229950000088 upadacitinib Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1